NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research

        • Research Overview
        • Clinical Research Facility
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • Oxford Blood Group
    • Case Studies
    • PPIE Strategy
    • PPIE News
    • PPI Researcher Guidance
    • Researchers: Post a PPIE opportunity
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events
Research Theme

Cardiovascular Medicine

You are here: Home > Research Overview > Cardiovascular Medicine > OxVALVE: Oxford Valve Study

OxVALVE: Oxford Valve Study

OxVALVE logo

The Oxford Valvular Heart Disease Population Study (OxVALVE) is a large research study of more than 4,000 subjects recruited from GP surgeries. It was established in 2009 because Valvular Heart disease (VHD) is poorly researched in comparison with other heart disease. We aim to discover, via a screening programme of adults aged over 65, whether early detection and treatment of VHD may improve the care pathways and health of patients in the long term. The cohort consists of volunteers over the age of 65, with no known VHD, who have been enrolled from seven GP surgeries within Oxfordshire.

The study is now in Phase 2, following-up participants to examine how often and how rapidly valve disease progresses

People who have taken part in screening for OxVALVE discuss their experiences of undergoing the screening, receiving their results, and ongoing participation in the study.

Objectives

Phase 1:

  • To discover the proportion of the population over 65 years of age within Oxfordshire who have VHD, via a screening programme based in GP surgeries.
  • To find out how acceptable this screening process is to patients, and any problems it brings to both them and the health service.
  • To identify the associated conditions that are linked to valve disease
  • To identify any biological markers that might indicate the presence of valve disease and/or it’s likely progression

Phase 2:

  • Medium-term follow-up of OxVALVE participants five years after initial recruitment to the study. It aims to define the rates of disease progression, risk markers for prognosis, and whether mild VHD is of clinical concern.
  • We assess activity levels, quality of life, and other impacts in subjects with and without valve disease.
  • We hope that our study of VHD will enable us to predict those who will require treatment to improve patient clinical outcomes. Conversely, we aim to identify those people who can be reassured that their valve disease does not require follow-up.

What’s measured?

  • Demographics and a medical history are obtained and a screening echocardiogram blood pressure and ECG are performed on each subject.
  • Blood samples are obtained for future research / DNA analysis.
  • Over 50% of those invites attended the screening programme, ratio male to female 1:1.
  • Phase two; five year follow up visits are now underway, the return rate for participants is approx. 65%

Achievements

  • Publication of the first 2,500 participant data in European Heart Journal June 2016.
  • OxVALVE results from the first 2,500 participant’s data have been presented by Prof Prendergast at several key conferences.
  • Valvular Heart Disease (VHD) has been detected in 51% overall with strong age relationship (the proportion rises to 71% in over-85s).
  • Echo screening for VHD has been proven to be both feasible and acceptable to patients.
  • VHD has been found to affect 45% of the population over 65 years of age, of which less than 6.4% are moderate or severe. Prevalence of VHD increased linearly with age.
  • A steering committee has been established to manage future OxVALVE projects, and cultivate links with other clinical research groups.
  • NHS Digital data linkage study on mortality undertaken with Primary Care Academic Group.
  • Several data mining projects completed.
  • Quantitative studies of valve disease with Cardiovascular Magnetic Resonance have demonstrated the ability to predict patients likely to require valve surgery in the near future.
  • OxVALVE has quantified the current burden of undiagnosed valve disease in the population.            
  • OxVALVE has allowed estimates of the predicted increasing burden of moderate/severe VHD due to the ageing population.
  • Preliminary findings from OxVALVE suggest that mild disease is very common in the general population, and may not require further follow-up.

Collaborations

  • Clinical Cardiovascular Research Facility (CCRF), University of Oxford
  • GE Healthcare
  • NIHR Oxford Biomedical Research Centre
  • School for Primary Care Research
  • Echo normal study
  • OxVasc Study
  • GE Healthcare
  • Novacor

Principal Investigators

Prof Bernard Prendergast & Prof Saul Myerson

Address: The OxVALVE Study Office, Room B15, Level 0, Cardiac Investigation Annexe, John Radcliffe Hospital, Headington, Oxford OX3 9DU

Phone: 01865 228927

Cardiovascular Medicine

  • Cardiovascular Medicine
  • Sub-theme 1: Identifying and validating new therapeutic targets
  • Sub-theme 2: Applying new technologies to improve personalised prevention and management of CVD
  • Sub-theme 3: Addressing maternal cardiovascular risk
  • NIHR–British Heart Foundation Cardiovascular Partnership
    • NIHR-BHF collaborative projects
    • NIHR-BHF highlights
    • NIHR-BHF news and events
  • OxVasc: Oxford Vascular Study
  • OxVALVE: Oxford Valve Study
  • Contacts
  • Videos
  • PPI Case Study
  • News

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre